[EFFECT] KAZIA THERAPEUTICS LTD SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

Analyzing...

12/23/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	December 22, 2025

Accession Number:

0001193125-25-326992

Submission Type:

POS AM

CIK:	0001075880
Company Name:	KAZIA THERAPEUTICS LTD
File Number:	333-276774

Source: View Original Filing on SEC EDGAR

Kazia Therapeuti

NASDAQ:KZIA

KZIA Rankings

#5051 Ranked by Market Cap

N/A Ranked by Dividends

KZIA Latest News

Jan 30, 2026

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Jan 27, 2026

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Jan 8, 2026

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Dec 22, 2025

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Dec 10, 2025

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

KZIA Latest SEC Filings

Feb 20, 2026

[SCHEDULE 13G/A] KAZIA THERAPEUTICS LTD Amended Passive Investment Disclosure

Feb 17, 2026

[SCHEDULE 13G] KAZIA THERAPEUTICS LTD Passive Investment Disclosure (>5%)

Feb 12, 2026

[SCHEDULE 13G/A] KAZIA THERAPEUTICS LTD Amended Passive Investment Disclosure

Jan 27, 2026

[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)

Jan 27, 2026

[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)

KZIA Stock Data

Market Cap 100.32M

Float 10.58M

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country Australia

City NEW SOUTH WALES 2113